Patents Assigned to ioGenetics, LLC
-
Patent number: 11640847Abstract: This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.Type: GrantFiled: July 6, 2020Date of Patent: May 2, 2023Assignee: IOGENETICS, LLCInventors: Robert D. Bremel, Jane Homan
-
Patent number: 11434259Abstract: The present invention relates to vaccine compositions and therapeutic interventions for treating and preventing infections and diseases caused by flaviviruses, including Zika, dengue, and Usutu virus. It also relates to compositions and methods for diagnosis and differential diagnosis of flaviviruses and co-endemic pathogens.Type: GrantFiled: January 25, 2017Date of Patent: September 6, 2022Assignee: IOGENETICS, LLCInventors: Robert D. Bremel, Jane Homan, Michael Imboden
-
Publication number: 20210265008Abstract: The present invention provides methods and systems for identifying and classifying patterns comprising the T cell exposed motifs and the frequencies of such motifs in collections of proteins that make up the human proteome, immunoglobulinome, T cell receptor repertoire or microbiome, and other proteomes of environmental of microbial origin, or subsets thereof. It further provides graphical representations that facilitate comparisons of T cell exposed motif patterns between samples or between time points. The present invention also provides methods and systems for identifying and classifying patterns in repertoires of cells including receptor bearing cells and cells of tissue samples and detecting patterns of utility in diagnosis and monitoring of health and disease.Type: ApplicationFiled: May 9, 2019Publication date: August 26, 2021Applicant: Iogenetics, LLCInventors: Robert D. BREMEL, Jane HOMAN
-
Patent number: 11069427Abstract: This invention relates to the identification of peptidase cleavage sites in proteins and in particular to identification protease cleavage by the endopeptidases. The present invention utilizes a bioinformatic methodology for prediction of peptidase cleavage sites based on principal component analysis and based on training sets obtained by experimental protein cleavage. This invention is not limited to training sets derived from CSL approaches, nor to any other experimental determination of cleavage site.Type: GrantFiled: June 9, 2014Date of Patent: July 20, 2021Assignee: IOGENETICS, LLCInventor: Robert D. Bremel
-
Patent number: 10799582Abstract: The present invention provides a means to prepare a product from domestic animal milk, blood or eggs which comprises an array of T-cell exposed motifs similar in identity, distribution and concentration to those found in human immunoglobulin variable regions and to prepare and apply the product as an immune modulating agent for administration either as a nutritional supplement or as a pharmaceutical product.Type: GrantFiled: July 10, 2015Date of Patent: October 13, 2020Assignee: IOGENETICS, LLCInventors: Robert D. Bremel, Jane Homan
-
Patent number: 10755801Abstract: The present invention provides methods and systems for identifying and classifying epitopes and use of that information to analyze proteins and peptides within proteins, especially potential epitopes, and to use the information to design synthetic peptides and proteins, analyze biopharmaceutical proteins, and diagnose autoimmune conditions. Peptides which are bound in MHC grooves comprise two sets of amino acids: those that face inwards into the groove and determine the binding affinity to the MHC molecule (the groove exposed motifs or GEM) and those which do not interact with the groove but rather are on the obverse side exposed outwardly to the T-cells (the T-cell exposed Motifs or TCEM). The present invention utilizes information related to the identity and physiochemical characteristics of the GEM and TCEM.Type: GrantFiled: July 10, 2015Date of Patent: August 25, 2020Assignee: IOGENETICS, LLCInventors: Robert D. Bremel, Jane Homan, Michael Imboden
-
Patent number: 10706955Abstract: This invention relates to processes for identifying peptide and polypeptide ligands for a binding partner by using principal component analysis of amino acids to derive vectors describing amino acid subsets corresponding to peptides with known binding affinities and then using this information in a neural network modeling process to derive binding prediction equations. These binding prediction equations are then used in the analysis of subsets of amino acids from a target source to identify peptides or polypeptides ligands in the target source that have affinity for a binding partner.Type: GrantFiled: March 21, 2011Date of Patent: July 7, 2020Assignee: IOGENETICS, LLCInventors: Robert D. Bremel, Jane Homan
-
Publication number: 20170039314Abstract: This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.Type: ApplicationFiled: September 13, 2012Publication date: February 9, 2017Applicant: IOGENETICS, LLCInventors: Rober D. Bremel, Jane Homan
-
Publication number: 20150284452Abstract: The present invention relates antimicrobial compositions, and in particular to antigen binding proteins comprising one or more domains that provide antimicrobial activity.Type: ApplicationFiled: November 13, 2013Publication date: October 8, 2015Applicant: IOGENETICS, LLCInventors: Robert Duane Bremel, Jane Homan, Michael Imboden, Brendan Keough
-
Patent number: 8703134Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: GrantFiled: February 6, 2013Date of Patent: April 22, 2014Assignees: ioGenetics, LLC, Arizona Board of Regents on Behalf of the University of ArizonaInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
-
Publication number: 20130330335Abstract: This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.Type: ApplicationFiled: March 21, 2011Publication date: December 12, 2013Applicant: IOGENETICS, LLCInventors: Robert D. Bremel, Jane Homan
-
Publication number: 20130230516Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: ApplicationFiled: February 6, 2013Publication date: September 5, 2013Applicants: Arizona Board of Regents on behalf of the University of Arizona, ioGenetics, LLCInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
-
Patent number: 8394379Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: GrantFiled: January 13, 2010Date of Patent: March 12, 2013Assignee: ioGenetics, LLCInventors: Michael Imboden, Michael Warren Riggs, Deborah A. Schaefer, Jane Homan
-
Publication number: 20100183611Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: ApplicationFiled: January 13, 2010Publication date: July 22, 2010Applicants: IOGENETICS, LLC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan
-
Publication number: 20100111976Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: September 24, 2009Publication date: May 6, 2010Applicant: IOGENETICS, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Publication number: 20100034824Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzyme) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: August 5, 2009Publication date: February 11, 2010Applicants: IOGENETICS, LLC, THE ARIZONA BOARD OF REGENTSInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer
-
Patent number: 7566447Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).Type: GrantFiled: October 20, 2005Date of Patent: July 28, 2009Assignees: Iogenetics, LLC, The Arizona Board of Regents on Behalf of the University of ArizonaInventors: Jane Homan, Michael Imboden, Michael Riggs, Stephane Carryn, Deborah A. Schaefer
-
Publication number: 20090098121Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: October 19, 2007Publication date: April 16, 2009Applicant: ioGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Publication number: 20080267943Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: October 19, 2007Publication date: October 30, 2008Applicant: ioGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Publication number: 20080269122Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: October 19, 2007Publication date: October 30, 2008Applicant: ioGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel